SG Americas Securities LLC Purchases Shares of 13,416 Puma Biotechnology, Inc. (NASDAQ:PBYI)

SG Americas Securities LLC purchased a new position in Puma Biotechnology, Inc. (NASDAQ:PBYI) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,416 shares of the biopharmaceutical company’s stock, valued at approximately $34,000.

Other institutional investors have also recently made changes to their positions in the company. Frazier Life Sciences Management L.P. boosted its stake in Puma Biotechnology by 8.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock valued at $9,984,000 after buying an additional 246,264 shares during the period. Acadian Asset Management LLC raised its holdings in shares of Puma Biotechnology by 2.0% in the 1st quarter. Acadian Asset Management LLC now owns 1,956,513 shares of the biopharmaceutical company’s stock valued at $10,366,000 after acquiring an additional 39,239 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Puma Biotechnology by 1.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,753,013 shares of the biopharmaceutical company’s stock valued at $5,715,000 after acquiring an additional 23,600 shares in the last quarter. Great Point Partners LLC boosted its position in shares of Puma Biotechnology by 10.6% during the 2nd quarter. Great Point Partners LLC now owns 1,486,544 shares of the biopharmaceutical company’s stock valued at $4,846,000 after acquiring an additional 142,916 shares during the last quarter. Finally, American Century Companies Inc. grew its holdings in shares of Puma Biotechnology by 98.5% during the second quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock worth $2,409,000 after purchasing an additional 366,653 shares in the last quarter. Institutional investors own 61.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. StockNews.com raised shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, October 23rd. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Puma Biotechnology in a report on Friday, August 2nd.

Puma Biotechnology Trading Down 1.4 %

NASDAQ PBYI opened at $2.79 on Wednesday. The company has a quick ratio of 1.23, a current ratio of 1.32 and a debt-to-equity ratio of 0.90. The stock’s 50-day simple moving average is $2.61 and its two-hundred day simple moving average is $3.42. Puma Biotechnology, Inc. has a twelve month low of $2.22 and a twelve month high of $7.73. The company has a market capitalization of $136.85 million, a price-to-earnings ratio of 14.68 and a beta of 1.09.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The company had revenue of $47.10 million for the quarter, compared to analysts’ expectations of $43.99 million. Puma Biotechnology had a return on equity of 18.36% and a net margin of 4.01%. During the same period last year, the firm posted $0.05 EPS. Research analysts forecast that Puma Biotechnology, Inc. will post 0.25 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Michael Patrick Miller sold 23,358 shares of the company’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $3.49, for a total value of $81,519.42. Following the completion of the sale, the director now owns 47,000 shares of the company’s stock, valued at approximately $164,030. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 23.70% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.